Trial description:
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Contact name:
Dr George Follows
Trial start date:
Friday, July 27, 2018
Trial end date:
Sunday, March 16, 2025
Trial tumour type:
Haematological
Show on Radiotherapy:
No
